达沙替尼治疗伊马替尼耐药晚期胃肠道间质瘤的无进展生存期关联
这项单臂临床试验采用贝叶斯设计,纳入50例伊马替尼耐药晚期胃肠道间质瘤患者,评估达沙替尼70mg每日两次的疗效。结果显示6个月无进展生存率总体为29%,pSRC表达亚组为50%,客观缓解率25%,提示达沙替尼可能对部分患者有活性。
要点
- 达沙替尼在伊马替尼耐药GIST中6个月PFS率为29%。
- pSRC表达亚组6个月PFS率达50%。
- 客观缓解率25%,含1例PDGFRA外显子18突变患者。
核心结论
- 达沙替尼可能对部分伊马替尼耐药GIST患者有活性。
- pSRC是否為预后生物标志物需进一步研究。
研究设计与样本
- 单臂临床试验,采用贝叶斯设计,无对照组。
- 纳入50例≥13岁伊马替尼耐药转移性GIST患者,来自14家肉瘤转诊中心。
- 达沙替尼70mg口服每日两次,随访至少5年。
主要发现
- 总体人群估计6个月PFS率为29%。
- 14例pSRC表达患者亚组6个月PFS率为50%。
- 客观肿瘤缓解率为25%,包括1例PDGFRA外显子18突变患者。
关键数值与推荐
- 主要终点6个月PFS估计,以大于30%作为活性药物证据,小于10%作为无效证据。
- 肿瘤反应采用Choi标准由当地站点评估。
- 前24周每8周、之后每12周行CT或MRI评估。
临床怎么用
- 达沙替尼可作为伊马替尼耐药GIST的潜在后续治疗选择之一。
- pSRC表达可能有助于筛选获益人群,但尚需验证。
局限性
- 单臂设计,无对照组。
- 样本量较小(50例)。
- pSRC为探索性亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate followed by regorafenib provides tumor control; however, additional active treatments are needed for most patients. OBJECTIVE: To evaluate the 6-month progression-free survival (PFS), tumor objective response, and overall survival rates in patients with GISTs treated with dasatinib. DESIGN, SETTING, AND PARTICIPANTS: This single-arm clinical trial used a Bayesian design to enroll patients 13 years or older with measurable imatinib-refractory metastatic GISTs treated at 14 sarcoma referral centers from June 1, 2008, through December 31, 2009. A control group was not included. Patients were followed up for survival for a minimum of 5 years from date of enrollment. Tumor imaging using computed tomography or magnetic resonance imaging was performed every 8 weeks for the first 24 weeks and every 12 weeks thereafter. Tumor response was assessed by local site using the Choi criteria. Treatment was continued until tumor progression, unacceptable toxic effects after reduction in drug dose, or patient or physician decision. Archival tumor tissue was evaluated for expression of the proto-oncogene tyrosine-protein kinase Src (SRC), phosphorylated SRC (pSRC), and succinate dehydrogenase complex iron sulfur subunit B (SDHB) proteins and for mutation in the V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and platelet-derived growth factor receptor α (PDGFRA) genes. Data analysis was performed from May 19, 2017, through December 20, 2017. INTERVENTIONS: Dasatinib, 70 mg orally twice daily. MAIN OUTCOMES AND MEASURES: The primary end point was the 6-month PFS estimate using greater than 30% as evidence of an active drug and less than 10% as evidence of inactive treatment. RESULTS: In this study, 50 patients were enrolled (median age, 60 years; age range, 19-78 years; 31 [62%] male and 19 [38%] female; 41 [82%] white), and 48 were evaluable for response. The estimated 6-month PFS rate was 29% in the overall population and 50% in a subset of 14 patients with pSRC in GISTs. Objective tumor response was observed in 25%, including 1 patient with an imatinib-resistant mutation in PDGFRA exon 18. CONCLUSIONS AND RELEVANCE: Dasatinib may have activity in a subset of patients with imatinib-resistant GISTs. Further study is needed to determine whether pSRC is a prognostic biomarker.
引用
- Schuetze SM, Bolejack V, Thomas DG, et al. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol. 2018. PMID: 29710216. doi:10.1001/jamaoncol.2018.0601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。